4D Molecular Therapeutics (FDMT) EBIT Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 183.45% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | -37.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.30% |
| Dec 31, 2025 | 126.22% |
| Sep 30, 2025 | -19.66% |
| Jun 30, 2025 | -40.04% |
| Mar 31, 2025 | -40.60% |
| Dec 31, 2024 | -53.11% |
| Sep 30, 2024 | -265.91% |
| Jun 30, 2024 | -32.11% |
| Mar 31, 2024 | -26.67% |
| Dec 31, 2023 | -27.62% |
| Sep 30, 2023 | 47.26% |
| Jun 30, 2023 | -13.05% |
| Mar 31, 2023 | -14.07% |
| Dec 31, 2022 | -15.97% |
| Sep 30, 2022 | -16.92% |
| Jun 30, 2022 | -274.22% |
| Mar 31, 2022 | -61.79% |
| Dec 31, 2021 | -21.26% |
| Sep 30, 2021 | -189.93% |
| Jun 30, 2021 | 49.86% |